Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziltivekimab - Novo Nordisk

Next Previous
Drug Profile

Ziltivekimab - Novo Nordisk

Alternative Names: COR 001; EX-6018; MEDI-5117; NN-6018; WBP-216

Latest Information Update: 02 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer MedImmune; Novo Nordisk
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders; Heart failure; Myocardial infarction
  • No development reported Kidney disorders
  • Discontinued Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 19 Dec 2025 Phase-III clinical trials in Myocardial infarction in Switzerland (SC) (NCT07276282)
  • 20 Oct 2025 Novo Nordisk plans a phase III trial in Myocardial infarction in Austrial, Denmark, Italy, Spain, Netherlands (SC) in October 2025 (CTIS2024-520364-34-00)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Kidney-disorders in China (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top